View Clinical Trial (Medical Research Study)
ESBA1008 Safety, Tolerability and Effects in Wet Age-related Macular Degeneration (AMD) Patients
| City: |
|
Fort Worth |
| State: |
|
Texas |
| Zip Code: |
|
76134 |
| Conditions: |
|
Exudative Age-related Macular Degeneration |
| Purpose: |
|
The purpose of this study is to evaluate the safety, tolerability and effects of an
investigational drug ESBA1008 for the treatment of exudative age-related macular
degeneration
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- primary subfoveal choroidal neovascularization (CNV) secondary to AMD, including
predominantly classic, minimally classic or occult lesions in study eye
- a new diagnosis of exudative AMD or evidence of recent disease progression within the
last 3 months in study eye
Exclusion Criteria:
- Study eye must not have been treated for wet AMD previously
- Study eye must not have any other ocular disease, condition, infection or recent
surgery that would interfere with vision or examination of the back of the eye
- Study eye must not have uncontrolled glaucoma and/or must not be missing a lens
- Current use or history of chronic therapy with systemic or topical ocular
corticosteroids
- Must not have medical condition that would preclude scheduled study visits,
completion of study or safe administration of study medication
- Must not have allergies to any component of the test article or sensitivity to
fluorescein dye
- Abnormal screening laboratory result
- Female of childbearing potential who are not using adequate birth control methods.
|
| NCT ID: |
|
NCT01304693 |
| Primary Contact: |
|
Alcon Call Center
Phone: 1-888-451-3937
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Fort Worth, Texas 76134
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|